Poseida Therapeutics, Inc. (PSTX) Tops Q3 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Nasdaq set for sharp drop as Amazon, Intel amplify AI spending worries
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil set for fourth monthly gain as Hormuz tanker attack highlights supply risks
Tweet
Share
E-mailGet Alerts PSTX Hot Sheet
Price: $9.50 --0%
Financial Fact:
Income tax (benefit) provision: -253
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Financial Fact:
Income tax (benefit) provision: -253
Today's EPS Names:
BNCC, ZVOI, SYRS, More
Join SI Premium – FREE
Poseida Therapeutics, Inc. (NASDAQ: PSTX) reported Q3 EPS of $0.21, $0.63 better than the analyst estimate of ($0.42). Revenue for the quarter came in at $71.75 million versus the consensus estimate of $16.25 million.
For earnings history and earnings-related data on Poseida Therapeutics, Inc. (PSTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Why Beijing could block the SpaceX-Tesla merger
- Standard Motor Products (SMP) Tops Q3 EPS by 4c
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
